Due to current HHS and NIH restructuring, some content on niaid.nih.gov is not being updated regularly. Please refer to clinicaltrials.gov and nih.gov for the most up-to-date information on NIH research.
Concepts represent early planning stages for program announcements, requests for applications, or solicitations for Council’s input. If NIAID publishes an initiative from one of these concepts, we link to it below. To find NIAID initiatives, go to Explore NIH Grant Opportunities.
Note: Council approval does not guarantee that a concept will become an initiative.
Table of Contents
Fiscal Year (FY) 2027 Division of Allergy, Immunology, and Transplantation (DAIT) Concepts
- Autoimmune Diseases Statistical and Clinical Coordinating Center (AD-SCCC)
- Atopic Dermatitis Research Network (ADRN)
Autoimmune Diseases Statistical and Clinical Coordinating Center (AD-SCCC)
Request for Applications—proposed FY 2027 initiative
Contact:
Jeffrey Rice
Jeffrey.rice@nih.gov
Objective: The Autoimmune Diseases Statistical and Clinical Coordinating Center (AD-SCCC) will provide clinical study development, regulatory support, management, site monitoring, repository management, manuscript production, study archiving, and biostatistical support for ongoing and future clinical trials in the areas of autoimmune diseases, mucosal immunology, and inborn errors of immunity while maintaining and supporting all relevant regulatory requirements.
Description: The Autoimmune Diseases Statistical and Clinical Coordinating Center (AD-SCCC) will provide essential support for the design, development, execution, and analysis of clinical research sponsored by NIAID in autoimmune diseases, diseases related to mucosal immunology, and inborn errors of immunity. The scope of clinical research to be supported by the AD-SCCC includes: 1) clinical trials in all phases to evaluate the safety and efficacy of investigational products and innovative approaches for disease treatment and prevention; 2) studies of underlying mechanisms of diseases under investigation as integral components of clinical trials; 3) clinical studies (e.g., genetic studies, microbiome studies, surveys of current therapies); and 4) surrogate/biomarker studies. The scope of statistical and clinical support functions to be performed by the AD-SCCC includes: 1) statistical design and analysis; 2) protocol development, study initiation, and closeout; 3) data coordinating and reporting; 4) safety oversight and pharmacovigilance center support; 5) clinical study collaboration portals; 6) management of biorepositories; and 7) technical and administrative support.
Atopic Dermatitis Research Network (ADRN)
Request for Applications—proposed FY 2027 initiative
Contact:
Mike Minnicozzi
minnicozzim@niaid.nih.gov
Objective: The objective of this initiative is to foster the integration of clinical and translational (multidisciplinary) research to further improve our understanding of skin immunology and defense mechanisms by focusing on differences in skin immune responses and structure/function between patients with AD and healthy individuals or controls with other conditions.
Description: This initiative renewal will continue support for NIAID’s long-standing Atopic Dermatitis Research Network (ADRN) program. This initiative will support U19 awards at research centers across the United States to conduct interdisciplinary and translational research in AD. The centers will coordinate their efforts through a Steering Committee and collaborate with each other through an opportunity fund. Although this is a renewal of the ADRN initiative, there will be a substantial change from the current clinical network structure. The new initiative will not include a UM1 award (Leadership Center) and will change the individual U01 clinical research center awards into U19 awards. Up to two projects per U19 award will be required in order to focus on supporting the high-quality mechanistic science that has been traditionally produced by this research network. In addition, the new initiative will provide opportunity funds for the conduct of single site or multi-site small, pilot trials or observational studies with primary mechanistic outcomes to ensure completion during the award period. Another primary goal of the opportunity fund will be to support junior investigators in order to provide them with opportunities to build a research background and foster their independence.